CA2095141A1 - Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents - Google Patents

Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents

Info

Publication number
CA2095141A1
CA2095141A1 CA002095141A CA2095141A CA2095141A1 CA 2095141 A1 CA2095141 A1 CA 2095141A1 CA 002095141 A CA002095141 A CA 002095141A CA 2095141 A CA2095141 A CA 2095141A CA 2095141 A1 CA2095141 A1 CA 2095141A1
Authority
CA
Canada
Prior art keywords
tumor
antibody
cells
antibodies
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002095141A
Other languages
English (en)
French (fr)
Inventor
Ingegerd Hellstrom
Karl E. Hellstrom
George Schreiber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2095141A1 publication Critical patent/CA2095141A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
CA002095141A 1990-11-05 1991-10-18 Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents Abandoned CA2095141A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60955790A 1990-11-05 1990-11-05
US609,557 1990-11-05

Publications (1)

Publication Number Publication Date
CA2095141A1 true CA2095141A1 (en) 1992-05-06

Family

ID=24441285

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002095141A Abandoned CA2095141A1 (en) 1990-11-05 1991-10-18 Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents

Country Status (4)

Country Link
EP (1) EP0556285A4 (ja)
JP (1) JPH06501705A (ja)
CA (1) CA2095141A1 (ja)
WO (1) WO1992007466A1 (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980896A (en) * 1989-06-30 1999-11-09 Bristol-Myers Squibb Company Antibodies reactive with human carcinomas
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5792456A (en) * 1994-08-04 1998-08-11 Bristol-Myers Squibb Company Mutant BR96 antibodies reactive with human carcinomas
WO1998009651A1 (fr) * 1996-09-03 1998-03-12 Chugai Seiyaku Kabushiki Kaisha COMPLEXES D'ANTICORPS ANTI-INTEGRINE α3
MY136203A (en) 1998-08-11 2008-08-29 Idec Pharma Corp Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
EP1616572B1 (en) 1998-11-09 2010-09-01 Biogen Idec Inc. Chimeric anti-CD20 antibody, rituxan, for use in the treatment of chronic lymphocytic leukemia
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
EP1918305A1 (en) 1999-08-11 2008-05-07 Biogen Idec Inc. New clinical parameters for determining hematologic toxicity prior to radioimmunotherapy
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US6451284B1 (en) 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
WO2003068821A2 (en) 2002-02-14 2003-08-21 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
US8287864B2 (en) 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
RS55723B1 (sr) 2003-11-05 2017-07-31 Roche Glycart Ag Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
DK1776384T3 (da) 2004-08-04 2013-09-02 Mentrik Biotech Llc VARIANT-Fc-REGIONER
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
UA108735C2 (uk) 2008-07-21 2015-06-10 Структурні варіанти антитіл для покращення терапевтичних характеристик
CN105168204A (zh) * 2015-09-06 2015-12-23 江志鑫 一种含有丝裂霉素的抗结肠癌药物组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same

Also Published As

Publication number Publication date
JPH06501705A (ja) 1994-02-24
EP0556285A1 (en) 1993-08-25
WO1992007466A1 (en) 1992-05-14
EP0556285A4 (en) 1993-10-27

Similar Documents

Publication Publication Date Title
CA2095141A1 (en) Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
Seon et al. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
US8409573B2 (en) Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
EP0764030B1 (en) Composition containing autoantibodies for tumor therapy and prophylaxis
US5165922A (en) Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
JP4854912B2 (ja) 癌に対する抗体
Weiner et al. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erb B-2 and CD16
AU782569B2 (en) Therapeutic binding agents against MUC-1 antigen and methods of their use
US20080019990A1 (en) Therapeutic binding agents against MUC-1 antigen and methods for their use
WO2013189516A1 (en) Method for treating a gd2 positive cancer
LV11624B (en) Immuno-stimulatory monoclonal antibodies
CN109195988A (zh) 用于增强超抗原介导的癌症免疫疗法效力的方法和组合物
FI114011B (fi) Suonensisäiseen käyttöön tarkoitetun immunoglobuliinin käyttö farmaseuttisen koostumuksen valmistamiseksi syöpäsairauksien hoitamiseksi
Cheng et al. Recent advances in immunotherapy and monoclonal antibody treatment of cancer
EP0234122A2 (en) Tumor therapy with biologically active anti-tumor antibodies
Sunkara Novel approaches to cancer chemotherapy
AU650080B2 (en) Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
US6440733B1 (en) Monoclonal antibodies recognizing antigens on the surface of endothelial cells of tumor vessel
Matsudaira et al. Target chemotherapy of anti-CD147 antibody-labeled liposome encapsulated GSH-DXR conjugate on CD147 highly expressed carcinoma cells
JPH115749A (ja) 癌治療医薬品組成物
Reisfeld Monoclonal antibodies in cancer immunotherapy
WO2023095929A1 (ja) 悪性腫瘍治療薬
KR20230111071A (ko) 렌바티닙을 포함하는 암의 방사면역치료 보조제
CN103687877B (zh) 人源化免疫调节单克隆抗体的变体
Yeh et al. Radioimmunotherapy of xenografted human bladder cancer using monoclonal antibody against blood group A-related antigen

Legal Events

Date Code Title Description
FZDE Dead